Adam Schoen is a partner in Brown Rudnick’s Global Life Sciences Practice Group with an emphasis on intellectual property. With over a decade of experience advising life sciences and medical device funds, companies and academic institutions, Adam helps his clients build, grow, invest in, buy and sell companies of all sizes all over the world. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence, licensing and other agreement work.

Adam has experience developing and implementing patent strategies across the life sciences industry, working with therapeutics, biologics, diagnostics, medical device and digital health companies. He works with a variety of technologies, such as small molecule therapeutics, biologics (including immunotherapeutics), next generation sequencing technologies, microfluidics and droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, neurology, spine), medical imaging technology (IVUS and OCT), mass spectrometry and digital health products. He manages patent portfolios of all sizes and develops strategies to maximize and protect intellectual property rights in both the United States and foreign jurisdictions.

Prior to law school, Adam was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals, Inc.